<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6401">
  <stage>Registered</stage>
  <submitdate>31/03/2017</submitdate>
  <approvaldate>31/03/2017</approvaldate>
  <nctid>NCT03099187</nctid>
  <trial_identification>
    <studytitle>A Study of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing Interstitial Lung Disease</studytitle>
    <scientifictitle>Multicenter, International, Double-blind, Two-Arm, Randomized, Placebo-controlled Phase II Trial of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing ILD</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2016-002744-17</secondaryid>
    <secondaryid>MA39189</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Lung Diseases, Interstitial</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Pirfenidone
Treatment: drugs - Placebo

Experimental: Pirfenidone - Participants will receive pirfenidone 267 mg capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.

Experimental: Placebo - Participants will receive matching placebo capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.


Treatment: drugs: Pirfenidone
Pirfenidone 267 mg capsules three times in a day.

Treatment: drugs: Placebo
Matching placebo capsules three times in a day.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Rate of Decline in Forced Vital Capacity (FVC) Over the 24-week Double-blind Treatment Period - Rate of decline in FVC will be measured in mL by daily handheld spirometer.</outcome>
      <timepoint>Up to Week 24</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Percent Predicted FVC - FVC will be measured in mL by daily handheld spirometer as well as by spirometry.</outcome>
      <timepoint>Baseline (Day 1) to Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Categorical Change in FVC of &gt;5% During Clinic Visits - Categorical change in FVC will be measured both by daily spirometry as well as by spirometry.</outcome>
      <timepoint>Baseline (Day 1) to Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Categorical Change in FVC of &gt;10% During Clinic Visits - Categorical change in FVC will be measured both by daily spirometry as well as by spirometry.</outcome>
      <timepoint>Baseline (Day 1) to Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Percent Predicted Diffusing Capacity of the Lung for Carbon Monoxide (DLco) - The DLco is a pulmonary function test that measures the capacity for the lung to carry out gas exchange between the inhaled breath and the pulmonary capillary blood vessels and the DLco %-predicted represents the DLco expressed as a percentage of the expected normal valued based on the participant's age, height, gender and ethnicity.</outcome>
      <timepoint>Baseline (Day 1) to Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in 6-minute Walk Distance (6MWD) - Comparison of 6-minute walk distance before beginning and after completing study therapy.</outcome>
      <timepoint>Baseline (Day 1) to Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in University of California, San Diego-Shortness of Breath Questionnaire Score - University of California, San Diego Shortness of Breath Questionnaire (SOBQ) consists of 24-item on a scale of 0 to 5 with 0=not at all and 5=maximal or unable to do because of breathlessness. The total scores is calculated by summation of the 24 items scores and transformed into 0-100, with 0= poor quality of life , and 100= excellent quality of life.</outcome>
      <timepoint>Baseline (Day 1) to Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Score in Leicester Cough Questionnaire Score - The Leicester Cough Questionnaire is a patient-reported questionnaire evaluating the impact of cough on quality of life. The questionnaire comprises 19 items. Each item assesses symptoms, or the impact of symptoms, over the last 2 weeks on a seven-point Likert scale. Scores in three domains (physical, psychological and social) are calculated as a mean for each domain (range 1 to 7). A total score (range 3 to 21) is also calculated by adding the domain scores together. Higher scores indicate better quality of life.</outcome>
      <timepoint>Baseline (Day 1) to Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Cough Visual Analog Scale (VAS) Score - Cough VAS are 100-mm linear scales on which participants indicate the severity of their cough; 0 mm represents no cough and 100 mm the worst cough ever.</outcome>
      <timepoint>Baseline (Day 1) to Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Total and Sub-scores of the Saint George's Respiratory Questionnaire (SGRQ) - SGRQ is a health related quality of life questionnaire consisting of 40 items in three areas: symptoms (respiratory symptoms and severity), activity (activities that cause or are limited by breathlessness) and impacts (social functioning and psychological disturbances due to airway disease). The total score is 0 to 100 with a higher score indicating poorer health status.</outcome>
      <timepoint>Baseline (Day 1) to Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants with Non-elective Hospitalization, Both Respiratory and all Cause - Participants with non-elective hospitalization will be reported.</outcome>
      <timepoint>Up to Week 91</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants with Investigator-reported Acute Exacerbations - Percentage of participants with acute exacerbation will be reported.</outcome>
      <timepoint>Baseline (Day 1) to Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to First Investigator-reported Acute Exacerbations - Time to first investigator reported acute exacerbations from start of treatment will be reported.</outcome>
      <timepoint>Baseline (Day 1) to Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression-free Survival (PFS) - PFS is defined as the time to the first occurrence of a &gt;10% absolute decline in percent predicted FVC, a &gt;50 m decline of 6MWD, or death.</outcome>
      <timepoint>Baseline (Day 1) to Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression-free Survival (PFS) - PFS is defined as the time to the first occurrence of a &gt;10% absolute decline in percent predicted FVC, non-elective respiratory hospitalization, or death.</outcome>
      <timepoint>Baseline (Day 1) to Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Death From any Cause - Time to first documented death from start of treatment will be reported.</outcome>
      <timepoint>Up to Week 91</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Death from Respiratory Diseases - Time to first documented death due to respiratory diseases from start of treatment will be reported.</outcome>
      <timepoint>Up to Week 91</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants With Treatment-emergent Adverse Events (TEAEs) - An adverse events is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</outcome>
      <timepoint>Baseline (Day 1) up to Week 80</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants With Dose Reductions and Treatment Interruptions - Number of participants with dose reduction and treatment interruptions will be reported.</outcome>
      <timepoint>From administration of the first dose of study drug to Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants With Abnormalities in 12-lead Electrocardiogram (ECG) - Number of participants with abnormalities in ECG will be reported.</outcome>
      <timepoint>Screening to Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants Withdrawn from Trial Treatment or Trial Discontinuations - Number of participants withdrawn from trial treatment or trial discontinuations will be reported.</outcome>
      <timepoint>Up to Week 91</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Age &gt;= 18-85 years

          -  Confirmed fibrosing ILD which, following multidisciplinary team review, cannot be
             classified with either high or moderate confidence as a specific idiopathic
             interstitial pneumonia or other defined ILD

          -  Progressive disease as considered by the investigator as participants deterioration
             within the last 6 months, which is defined as a rate of decline in forced vital
             capacity (FVC) &gt;5% or a significant symptomatic worsening not due to cardiac,
             pulmonary vascular or other causes

          -  Extent of fibrosis &gt;10% on high-resolution computed tomography

          -  Forced vital capacity &gt;= 45% of predicted value

          -  Diffusing capacity of the lung for carbon monoxide (DLco) &gt;= 30% of predicted value

          -  Forced expiratory volume in 1 second/FVC ratio &gt;= 0.7

          -  Able to do 6-minute walk distance (6MWD) &gt;= 150 meters

          -  For women of childbearing potential: agreement to remain abstinent or use a
             non-hormonal or hormonal contraceptive method with a failure rate of &lt; 1% per year
             during the treatment period and for at least 90 days after the last dose of
             pirfenidone

          -  For men, agreement to remain abstinent or use contraceptive measures, and agreement to
             refrain from donating sperm</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Diagnosis with moderate or high confidence of nonspecific interstitial pneumonia and
             any ILD with an identifiable cause such as connective tissue disease-ILD, chronic
             hypersensitivity pneumonitis, or others

          -  Diagnosis of idiopathic pulmonary fibrosis independent of the confidence level

          -  History of unstable angina or myocardial infarction during the previous 6 months

          -  Treatment with high dose systemic corticosteroids, or any immunosuppressant other than
             mycophenolate mofetil/acid (MMF), at any time within the 4 weeks of the screening
             period. Participants being treated with MMF should be on a stable dose that is
             expected to remain stable throughout the trial and was started at least 3 months prior
             to screening

          -  Participants previously treated with pirfenidone or nintedanib

          -  Participants treated with N-acetyl-cysteine for fibrotic lung disease, at any time
             within the 4 weeks of the screening period

          -  Drug treatment for any type of pulmonary hypertension

          -  Participation in a trial of an investigational medicinal product within the last 4
             weeks

          -  Significant other organ co-morbidity including hepatic or renal impairment

          -  Predicted life expectancy &lt; 12 months or on an active transplant waiting list

          -  Use of any tobacco product in the 12 weeks prior to the start of screening, or any
             unwillingness to abstain from their use through to the Follow-up Visit

          -  Illicit drug or alcohol abuse within 12 months prior to screening

          -  Planned major surgery during the trial

          -  Hypersensitivity to the active substance or to any of the excipients of pirfenidone

          -  History of angioedema

          -  Concomitant use of fluvoxamine

          -  Clinical evidence of any active infection

          -  Any history of hepatic impairment, elevation of transaminase enzymes, or liver
             function test results as: Total bilirubin above the upper limit of normal (ULN),
             Aspartate aminotransferase or alanine aminotransferase &gt;1.5 × ULN, and Alkaline
             phosphatase &gt;2.0 × ULN

          -  Creatinine clearance &lt; 30 milliliter (mL) per minute, calculated using the
             Cockcroft-Gault formula

          -  Any serious medical condition, clinically significant abnormality on an
             Electrocardiogram (ECG) at screening, or laboratory test results

          -  An ECG with a heart rate corrected QT interval using Fridericia's formula as &gt;= 500
             milliseconds at screening, or a family or personal history of long QT syndrome</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>14/05/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>250</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>17/01/2020</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC,WA</recruitmentstate>
    <hospital>Royal Prince Alfred Hospital - Camperdown</hospital>
    <hospital>John Hunter Hospital; Respiratory Department; Respiratory Department - New Lambton Heights</hospital>
    <hospital>Princess Alexandra Hospital, Department of Respiratory and Sleep Medicine - Brisbane</hospital>
    <hospital>Northside Heart and Lung - Nundah</hospital>
    <hospital>Royal Adelaide Hospital; Respiratory Clinical Trials, Chest Clinic - Adelaide</hospital>
    <hospital>Bowen Centre Austin Health; Institute for Breathing and Sleep - Heidelberg</hospital>
    <hospital>The Alfred Hospital - Prahan</hospital>
    <hospital>Fiona Stanley Hospital; Advanced Lung Disease Unit - Murdoch</hospital>
    <postcode>2050 - Camperdown</postcode>
    <postcode>2305 - New Lambton Heights</postcode>
    <postcode>4102 - Brisbane</postcode>
    <postcode>4012 - Nundah</postcode>
    <postcode>5052 - Adelaide</postcode>
    <postcode>3084 - Heidelberg</postcode>
    <postcode>3181 - Prahan</postcode>
    <postcode>6150 - Murdoch</postcode>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Brno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Jihlava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Olomouc</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Praha 2</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Aarhus C</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Hellerup</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Odense C</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bad Berka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Gießen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Heidelberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>München</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Athens</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Chaidari</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Heraklio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Dublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Galway</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Beer Sheba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Haifa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Jerusalem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Kfar Saba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Petach Tikva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Rehovot</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Emilia-Romagna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lazio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lombardia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Marche</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Piemonte</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Sicilia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Toscana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gdansk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lodz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Aveiro</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Coimbra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Lisboa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Porto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Vila Nova De Gaia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Cantabria</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Birmingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Bristol</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cambridge</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Edinburgh</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Exeter</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leicester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Sheffield</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Southampton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Stoke on Trent</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Hoffmann-La Roche</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate the efficacy and safety of pirfenidone in
      participants with fibrosing interstitial lung disease (ILD) who cannot be classified with
      moderate or high confidence into any other category of fibrosing ILD by multidisciplinary
      team (MDT) review ("unclassifiable" ILD).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03099187</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trials</name>
      <address>Hoffmann-La Roche</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Reference Study ID Number: MA39189 www.roche.com/about_roche/roche_worldwide.htm</name>
      <address />
      <phone>888-662-6728 (U.S. and Canada)</phone>
      <fax />
      <email>global-roche-genentech-trials@gene.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>